Loading...
XNASCARA
Market cap19mUSD
Dec 27, Last price  
0.36USD
1D
-19.98%
1Q
18.03%
Jan 2017
-96.12%
IPO
-97.15%
Name

Cara Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CARA chart
P/E
—
P/S
0.94
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.57%
Rev. gr., 5y
9.26%
Revenues
21m
-49.92%
01,190,00011,964,0003,177,0003,803,00086,000911,00013,469,00019,886,000135,082,00023,028,00041,867,00020,968,000
Net income
-119m
L+42.08%
-9,806,000-6,271,000-3,963,000-17,745,000-24,690,000-57,280,000-58,125,000-74,013,000-106,373,0008,410,000-88,193,000-83,413,000-118,513,000
CFO
-92m
L+16.95%
-6,845,000-6,031,0002,829,000-17,642,000-21,478,000-47,381,000-54,827,000-22,301,000-109,225,000-5,487,000-60,087,000-78,730,000-92,078,000
Earnings
Mar 03, 2025

Profile

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
URL
https://www.caratherapeutics.com/
IPO date
Jan 31, 2014
Employees
106
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
20,968
-49.92%
41,867
81.81%
23,028
-82.95%
Cost of revenue
142,333
129,402
113,665
Unusual Expense (Income)
NOPBT
(121,365)
(87,535)
(90,637)
NOPBT Margin
Operating Taxes
(2,061)
(248)
Tax Rate
NOPAT
(121,365)
(85,474)
(90,389)
Net income
(118,513)
42.08%
(83,413)
-5.42%
(88,193)
-1,148.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,117
311
44,969
BB yield
-2.78%
-0.05%
-7.28%
Debt
Debt current
1,918
1,755
Long-term debt
49,255
3,836
5,591
Deferred revenue
Other long-term liabilities
9,604
Net debt
(51,503)
(150,995)
(229,443)
Cash flow
Cash from operating activities
(92,078)
(78,730)
(60,087)
CAPEX
(2,375)
(43)
(39)
Cash from investing activities
43,461
128,707
(4,751)
Cash from financing activities
38,151
311
46,608
FCF
(125,603)
(85,818)
(88,874)
Balance
Cash
100,758
145,399
167,035
Long term investments
11,350
69,754
Excess cash
99,710
154,656
235,638
Stockholders' equity
(684,951)
(567,851)
(481,063)
Invested Capital
785,203
728,548
712,258
ROIC
ROCE
EV
Common stock shares outstanding
54,149
53,654
50,719
Price
0.74
-93.08%
10.74
-11.82%
12.18
-19.50%
Market cap
40,233
-93.02%
576,239
-6.72%
617,755
-14.79%
EV
(11,270)
425,244
388,312
EBITDA
(121,106)
(87,287)
(90,389)
EV/EBITDA
0.09
Interest
604
248
Interest/NOPBT